Company intelligence / Profile preview

Signal Genetics

Carlsbad, California, USA

Ownership: Private
Development stage: Other

Overview

Signal Genetics, Inc. commercialized molecular diagnostic tests for multiple myeloma, notably the MyPRS® microarray-based gene expression profile (GEP) assay, which provided prognostic information to guide treatment decisions[2][4]. The company focused exclusively on blood cancers, leveraging an exclusive license to research from the University of Arkansas for Medical Sciences (UAMS)[4][6].

Therapeutic areas: HematologyOncology
Modalities: Gene expression profilingCytogenetic testingMolecular diagnostics
Industry: Molecular Diagnostics

Partnerships

University of Arkansas for Medical Sciences (UAMS, exclusive research and lab services partnership)[4][6]Neogenomics Laboratories (commercialization partnership)[1]

Beyond the preview

Go deeper on Signal Genetics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Signal Genetics.

Explore the full profile